Anavex Life Sciences Corp (AVXL)

[Rubyred77]

Bringing up some old news that many probably forgot about


https://act-ad.org/q-a-with-anavex/

Our lead compound, ANAVEX 2-73 is an orally available drug candidate that targets sigma-1 and muscarinic receptors. Our research shows sigma-1 receptors to be the key cellular survival proteins in neurodegenerative diseases. Our drug therapeutic targets the sigma-1 receptor in order to activate a “Quality Control.”

Q: What is your take on the current state of Alzheimer’s research?
A: I understand that the research resources available for Alzheimer’s are still much lower than for cancer. Regarding the clinical development, the recent clinical trials targeting and reducing Abeta directly, unfortunately, did not show fully positive outcomes. What we believe we are doing differently is that we are trying to aim for the potential cause of the Abeta aggregation, not just to target Abeta. We believe our drug is targeting the disease in a more upstream manner and possibly addressing the cause of the disease.

It is also important to point out we are a small company, not a big pharmaceutical commercializing drugs. We realize wall these trial failures have led to some fear in treating this area. Although recent trial disappointments have occurred; research should not be restricted, rather further supported. We are happy there are organizations such as ACT-AD helping get this voice out there.


https://www.anavex.com/press-releases/-anavex-life-sciences-to-present-at-the-5th-annual-mental-health-parity-addiction-equity-act-business-roundtable-in-washington%2C-dc

“It is important for panelists such as Dr. Missling to attend in order to lend his expertise in developing therapies for diseases such as Alzheimer’s disease as well as other neurological disorders with high unmet needs.”

The Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA) requires group health plans and health insurance issuers to ensure that financial requirements (such as co-pays, deductibles) and treatment limitations (such as visit limits) applicable to mental health or substance use disorder (MH/SUD) benefits are no more restrictive than the predominant requirements or limitations applied to substantially all medical/surgical benefits.